Physician profile
Uzma Samadani
NPI 1407916703
$20,123.25
in general payments reported to CMS, 2019-2025
12 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,272 · 2021: $4,376 · 2022: $1,919 · 2023: $448 · 2024: $115 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $14,180.59 | 2019-2024 | Limitorr, Cusa Clarity, Integra Flow Regulating Valve Low Flow |
| Medtronic, INC. | $4,106.94 | 2021-2022 | |
| Abbott Laboratories | $740.28 | 2019-2025 | Eterna, Proclaim |
| Medtronic USA, INC. | $522.00 | 2019-2020 | |
| Derma Sciences, INC. | $148.22 | 2019 | |
| Nevro Corp. | $126.67 | 2020 | |
| Zimvie INC. | $122.66 | 2023 | |
| Spineguard, INC. | $106.66 | 2023 | |
| Boston Scientific Corporation | $22.89 | 2022 | |
| Acadia Pharmaceuticals INC | $17.85 | 2024 | Nuplazid |
| Stryker Corporation | $15.05 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $13.44 | 2023 | Fycompa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Samadani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.